Vitamin D3 and calcidiol are not equipotent

Journal of Steroid Biochemistry and Molecular Biology

Volumn 164, Issue , 2016, Pages 205-208

  Navarro Valverde, Cristina ^a   Sosa Henríquez, Manuel ^b   Alhambra Expósito, Maria Rosa ^c   Quesada Gómez, José Manuel ^c  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^c UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

Calcidiol; Osteoporosis; Vitamin D3

Indexed keywords

CALCIFEDIOL; COLECALCIFEROL; 25-HYDROXYVITAMIN D; BONE DENSITY CONSERVATION AGENT; VITAMIN; VITAMIN D;

BIOCHEMICAL ANALYSIS; DRUG POTENCY; HUMAN; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; REVIEW; THERAPY EFFECT; VITAMIN BLOOD LEVEL; AGED; ANALOGS AND DERIVATIVES; BLOOD; FEMALE; MIDDLE AGED; OSTEOPOROSIS;

AGED; BONE DENSITY CONSERVATION AGENTS; CALCIFEDIOL; CHOLECALCIFEROL; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; VITAMIN D; VITAMINS;

EID: 84957686411     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2016.01.014     Document Type: Review

References (33)

1. [1] Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Dietary Reference Intakes for Calcium and Vitamin D, (2011). http://www.ncbi.nlm.nih.gov/books/NBK56070/ (accessed 03.11.15).
2. [2] Holick, M.F., Binkley, N.C., Bischoff-Ferrari, H.A., Gordon, C.M., Hanley, D.A., Heaney, R.P., et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96 (2011), 1911–1930, 10.1210/jc.2011-0385.
3. [3] Dawson-Hughes, B., Mithal, A., Bonjour, J.-P., Boonen, S., Burckhardt, P., Fuleihan, G.E.-H., et al. IOF position statement: vitamin D recommendations for older adults. Osteoporos. Int. 21 (2010), 1151–1154, 10.1007/s00198-010-1285-3.
4. [4] van Schoor, N.M., Lips, P., Worldwide vitamin D status. Best Pract. Res. Clin. Endocrinol. Metab. 25 (2011), 671–680, 10.1016/j.beem.2011.06.007.
5. [5] Hilger, J., Friedel, A., Herr, R., Rausch, T., Roos, F., Wahl, D.A., et al. A systematic review of vitamin D status in populations worldwide. Br. J. Nutr. 111 (2014), 23–45, 10.1017/S0007114513001840.
6. [6] Holick, M.F., Vitamin D deficiency. N. Engl. J. Med. 357 (2007), 266–281, 10.1056/NEJMra070553.
7. [7] Bouillon, R., Carmeliet, G., Verlinden, L., van Etten, E., Verstuyf, A., Luderer, H.F., et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr. Rev. 29 (2008), 726–776, 10.1210/er.2008-0004.
8. [8] Díez-Pérez, A., Olmos, J.M., Nogués, X., Sosa, M., Díaz-Curiel, M., Pérez-Castrillón, J.L., et al. Risk factors for prediction of inadequate response to antiresorptives. J. Bone Miner. Res. 27 (2012), 817–824, 10.1002/jbmr.1496.
9. [9] Peris, P., Martínez-Ferrer, A., Monegal, A., Martínez de Osaba, M.J., Muxi, A., Guañabens, N., 25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis. Bone 51 (2012), 54–58, 10.1016/j.bone.2012.03.026.
10. [10] Bischoff-Ferrari, H.A., Shao, A., Dawson-Hughes, B., Hathcock, J., Giovannucci, E., Willett, W.C., Benefit-risk assessment of vitamin D supplementation. Osteoporos. Int. 21 (2010), 1121–1132, 10.1007/s00198-009-1119-3.
11. [11] Sosa, M., Láinez, P., Arbelo, A., Navarro, M.C., The effect of 25-dihydroxyvitamin D on the bone mineral metabolism of elderly women with hip fracture. Rheumatology (Oxford) 39 (2000), 1263–1268 http://www.ncbi.nlm.nih.gov/pubmed/11085807 (accessed 03.11.15).
12. [12] Garcia-Delgado, I., Prieto, S., Gil-Fraguas, L., Robles, E., Rufilanchas, J.J., Hawkins, F., Calcitonin, etidronate, and calcidiol treatment in bone loss after cardiac transplantation. Calcif. Tissue Int. 60 (1997), 155–159 http://www.ncbi.nlm.nih.gov/pubmed/9056163 (accessed 03.11.15).
13. [13] Rizzoli, R., Boonen, S., Brandi, M.-L., Bruyère, O., Cooper, C., Kanis, J.A., et al. Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr. Med. Res. Opin. 29 (2013), 305–313, 10.1185/03007995.2013.766162.
14. [14] Stamp, T.C., Intestinal absorption of 25-hydroxycholecalciferol. Lancet (London, England) 2 (1974), 121–123 http://www.ncbi.nlm.nih.gov/pubmed/4135557 (accessed 03.11.15).
15. [15] Haddad, J.G., Rojanasathit, S., Acute administration of 25-hydroxycholecalciferol in man. J. Clin. Endocrinol. Metab. 42 (1976), 284–290, 10.1210/jcem-42-2-284.
16. [16] Jetter, A., Egli, A., Dawson-Hughes, B., Staehelin, H.B., Stoecklin, E., Goessl, R., et al. Pharmacokinetics of oral vitamin D(3) and calcifediol. Bone 59 (2014), 14–19 http://www.ncbi.nlm.nih.gov/pubmed/24516879 (accessed 03.11.15).
17. [17] Bischoff-Ferrari, H.A., Dawson-Hughes, B., Stöcklin, E., Sidelnikov, E., Willett, W.C., Edel, J.O., et al. Oral supplementation with 25(OH)D 3 versus vitamin D 3: effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity. J. Bone Miner. Res. 27 (2012), 160–169, 10.1002/jbmr.551.
18. [18] Herrera Martínez, A., Viñals Torràs, M., Muñoz Jiménez, M.C., Arenas de Larriva, A.P., Molina Puerta, M.J., Manzano García, G., Á. Gálvez Moreno, M., Calañas-Continente, A., Encefalopatía metabñlica secundaria a intoxicaciñn por vitamina D. Nutr Hosp. 31 (2015), 1449–1451.
19. [19] García Doladé, N., Cereza García, G., Madurga Sanz, M., Montero Corominas, D., Risk of hypercalcemia and hipervitaminosis D induced by calcifediol. Review of cases reported to the Spanish Pharmacovigilance System. Med. Clin. (Barc.) 141 (2013), 88–89.
20. [20] Mata-Granados, J.M., Quesada Gomez, J.M., Luque de Castro, M.D., Fully automatic method for the determination of fat soluble vitamins and vitamin D metabolites in serum. Clin. Chim. Acta 403:1–2 (2009), 126–130.
21. [21] Durup, D., Jørgensen, H.L., Christensen, J., Schwarz, P., Heegaard, A.M., Lind, B., A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: the CopD study. J. Clin. Endocrinol. Metab. 97 (2012), 2644–2652.
22. [22] Smith, J.E., Goodman, D.S., The turnover and transport of vitamin D and of a polar metabolite with the properties of 25-hydroxycholecalciferol in human plasma. J. Clin. Invest. 50:10 (1971), 2159–2167.
23. [23] Stamp, T.C., Intestinal absorption of 25-hydroxycholecalciferol. Lancet ., 2(121), 1974.
24. [24] Haddad, J.G., Stamp, T.C., Circulating 25-hydroxyvitamin D in man. Am. J. Med. 57 (1974), 57–62.
25. 3. Proc. Natl. Acad. Sci. U. S. A. 61 (1968), 1503–1516.
26. [26] Reeve, L.E., Jorgensen, N.A., DeLuca, H.F., Vitamin D compounds in cow's milk. J. Nutr. 112 (1982), 667–672.
27. [27] Institute of Medicine. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium Vitamin D, and Fluoride, National Academy Press, Washington D.C. (1997).
28. [28] W. Chan, J. Brown, S.M. Lee, D.H. Buss. Meat, poultry and game. Fifth supplement to the Fifth Edition of McCance and Widdowson's the Composition of foods. Cambridge/London, Royal Society of Chemistry/Ministery of Agriculture, Fisheries and Food (1995).
29. [29] H.F. DeLuca. The metabolism, physiology, and function of vitamin D. In: Kumar R, editor. Vitamin D: Basic and Clinical Aspects. Boston: M. Nijhoff Publishers (1984).
30. [30] Barger-Lux, M.J., Heaney, R.P., Dowell, S., Chen, T.C., Holick, M.F., Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men. Osteoporos Int. 8 (1988), 222–230.
31. [31] Hahn, T.J., Halstead, L.R., Teitelbaum, S.L., Hahn, B.H., Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration. J. Clin. Invest. 64 (1979), 655–665.
32. [32] Francis, R.M., Peacock, M., Storer, J.H., Davies, A.E., Brown, W.B., Nordin, B.E., Calcium malabsorption in the elderly: the effect of treatment with oral 25-hydroxyvitamin D3. Eur. J. Clin. Invest. 13 (1983), 391–396.
33. [33] Russo, S., Carlucci, L., Cipriani, C., Ragno, A., Piemonte, S., Fiacco, R.D., Pepe, J., Fassino, V., Arima, S., Romagnoli, E., Minisola, S., Metabolic changes following 500 μg monthly administration of calcidiol: a study in normal females. Calcif. Tissue Int. 89 (2011), 252–257.